Orginal from: genomeweb

The EU's Unified Patent Court last week ruled in favor of Myriad Genetics in its patent dispute with South Korean firm GXD-Bio.

In its ruling, the court invalidated a GXD-Bio patent covering breast cancer testing and rejected the company's claims that Myriad's EndoPredict breast cancer test infringed on its intellectual property.

The decision allows Myriad to continue marketing the test in Europe. Additionally, the court ordered GXD-Bio to cover Myriad's legal costs related to the suit.

GXD-Bio originally brought the suit in July 2024, claiming that the EndoPredict test, which is used to predict breast cancer recurrence, infringed its patent EP 3,346,403, which concerns gene expression testing. The patent in question was originally owned by Albion and Gencurix, from whom GXD-Bio purchased it in May 2024.

GXD-Bio has two months following the decision to bring an appeal.

Source: EU Unified Patent Court Rules in Favor of Myriad Genetics in Breast Cancer IP Dispute